To determine whether using a radiolabelled analog of 5-FU, [18F]-5-fluorouracil, for PET/CT
imaging can visually demonstrate differential chemotherapy delivery to known tumor sites
before and after administration of bevacizumab and determine the optimal timing of
bevacizumab administration to maximize the chemotherapy delivery into the tumor for improved
cancer treatment.